Abstract: Rapid delivery of an intravenous fluid bolus is commonly used in pediatric emergency care for the treatment of shock and hypotension. Early fluid delivery targeted at shock reversal results in improved patient outcomes, yet current methods of fluid resuscitation often limit the ability of providers to achieve fluid delivery goals. We report on the early clinical experience of a new technique for rapid fluid resuscitation. The LifeFlow ® infuser is a manually operated device that combines a syringe, automatic check valve, and high-flow tubing set with an ergonomic handle to enable faster and more efficient delivery of fluid by a single health care provider. LifeFlow is currently FDA-cleared for the delivery of crystalloid and colloids. Four cases are presented in which the LifeFlow device was used for emergent fluid resuscitation: a 6-month-old with septic shock, a 2-year-old with intussusception and shock, an 11-year-old with pneumonia and septic shock, and a 15-year-old with trauma and hemorrhagic shock.
Introduction
Children who present to the emergency department (ED) with shock have a 5-7% risk of mortality, and each hour of delay in shock reversal results in greater than a twofold increase in the odds of death. 1 Children with decompensated shock (prolonged capillary refill plus hypotension) are at the highest risk, with over 30% mortality. 1 Earlier fluid delivery targeted at shock reversal results in decreased morbidity, 1-3 mortality, 1, [3] [4] [5] [6] [7] [8] and hospital length of stay (LOS). 3, 7, [9] [10] [11] [12] For example, in a prospective cohort study evaluating adherence with guideline recommendations for fluid resuscitation in pediatric septic shock, patients for whom all aspects of the protocol were met had a 57% shorter hospital LOS. 9 In two retrospective cohort studies of protocolized severe sepsis care, adherence to the protocol resulted in earlier initiation of rapid fluid boluses, a larger total volume of fluid administered in the ED, less organ dysfunction, and shorter pediatric intensive care unit and hospital LOS. 2, 3 In a separate study of a sepsis quality improvement initiative, a sepsis bundle was initiated that included intravenous (IV) fluid boluses directed at the rapid reversal of shock. 7 The odds of death in this study were five times higher in children who did not receive bundle-compliant care. 7 Rapid restoration of intravascular volume may be required to correct hypotension and reverse shock in a variety of pediatric emergencies. In children with decompensated shock from conditions such as hypovolemia, sepsis, hemorrhage, and anaphylaxis, cardiovascular collapse may be imminent and rapid fluid bolus therapy is essential. 13, 14 A variety of methods are currently used for fluid delivery in children, including gravity infusion, IV infusion pumps, pressure bags, mechanical rapid infusers, and the use of manual syringes (the push-pull technique [PPT] or disconnect-reconnect technique [DRT] ). Gravity flow is universally slow, and while the addition of a pressure bag inflated to 300 mmHg may modestly speed the infusion rate, this technique requires constant re-inflation to achieve consistently increased speed. 15, 16 This method also carries the risk of air embolism. 17 Infusion pumps deliver a maximum rate of 1,000 mL/hr and can achieve 60 mL/kg over 15 mins only in patients weighing <4 kg, but are still commonly used as a method of fluid bolus delivery. 9, 12 With PPT and DRT, providers may be able to achieve the guidelinerecommended rates of infusion, 17, 18 but these methods are complex and labor-intensive, and both techniques may introduce bacterial contamination into the sterile stopcock. [19] [20] [21] [22] Mechanical rapid infusers are expensive, require highly trained staff, tend to be located only in larger EDs, and function best with large-gauge IV catheters. Finally, with most of these methods it may be difficult to quickly and efficiently deliver an accurate 10-20 mL/kg fluid bolus, quickly reassess patient response, and deliver an additional bolus if necessary. LifeFlow is a novel, FDA-cleared device for delivering measured boluses of crystalloids and colloids. The device packages a 10 mL spring-loaded syringe, large-bore inlet tubing, and an automatic check valve into a lightweight ergonomic device which facilitates rapid, controlled fluid delivery by a single health care provider (Figure 1) . In a simulation study comparing flow through common IV gauges, LifeFlow facilitated infusion two to four times as fast as standard techniques. (Figure 2) . 23 The device can be setup quickly in emergency situations, and may help avoid the nosocomial infection risks associated with PPT. [19] [20] [21] [22] In a recent study of LifeFlow at Yale New Haven Children's Hospital, teams of providers were asked to treat a simulated 10 kg patient with septic shock. For the fluid resuscitation element of the scenario, teams were randomized to LifeFlow, PPT, and pressure bag for the delivery of three 20 mL/kg boluses of fluid. Completion of the 60 mL/kg of fluid was fastest with the LifeFlow device, and participants judged the complexity of fluid delivery to be the lowest with LifeFlow, as measured by the National Aeronautical and Space Administration Task Load Index (NASA-TLX). 24 In a similar study, individual nurse and paramedic providers were asked to provide all patient care tasks for an adult-sized patient with septic shock, including assessment, fluid delivery, antibiotics, and documentation. Time to completion of three 500 mL fluid boluses required 7.8 mins with LifeFlow, compared to 20 mins with a pressure bag, and completion of all patient care tasks took 50% longer when a pressure bag was used as the infusion method (22.8 vs 36.3 mins). 25 The following case series illustrates the use of LifeFlow in children with shock resulting from a variety of emergency conditions. In each of these diverse cases, the patient received early and rapid fluid resuscitation, resulting in significant hemodynamic improvement. All patients subsequently experienced full recovery and were discharged home with no further sequelae.
The reporting of these cases has been approved by the WakeMed Institutional Review Board, Raleigh, NC. The parents of each patient have given written and informed consent to allow the publication of patient case details.
Cases

Case 1
A 6-month-old boy with a 2-day history of viral symptoms was found to be gray and unresponsive in his crib. The caregiver started cardiopulmonary resuscitation and called 911. Emergency medical services (EMS) found patient to be mottled and unresponsive with a heart rate (HR) of 230 beats per minute (BPM) and a palpable pulse. An IV catheter was inserted, and two doses of adenosine were given for presumed supraventricular tachycardia (SVT) without effect. On arrival to the ED, the HR was 245 BPM and he remained unresponsive, with a capillary refill time of >4 s. After a third dose of adenosine was administered, the IV catheter infiltrated and several additional attempts were made to establish IV access. He then developed apparent seizure activity, with eye deviation and symmetric twitching of all extremities. Bedside ultrasound revealed a hyperdynamic heart with subjectively increased heart function and complete inspiratory collapse of the inferior vena cava (IVC). An arterial blood gas showed a pH of 6.7 and lactate of 9 mmol/L. Due to these findings and HR variability, the presumed diagnosis was changed from SVT to septic shock. After IV access was re-established, a bolus of 40 mL/kg of normal saline was infused with LifeFlow through a 22-gauge IV catheter in the right antecubital vein in <5 mins. This led to an immediate decrease in HR to 170 BPM. He was subsequently electively intubated due to shock, altered mental status, and presumed seizures. An additional 160 mL/kg of normal saline was infused with LifeFlow in 40 mL/kg increments, after which he achieved improved perfusion and stable vital signs. No vasopressors were required. Lactate decreased to <2 mmol/L in 4 hrs, and serum creatinine decreased from 1.1 to 0.4 mg/dL within 12 hrs. He was extubated within 48 hrs and was neurologically normal. He was subsequently diagnosed with hemophagocytic lymphohistiocytosis and septic shock. 
Discussion
In each of the cases presented is this report, a child with shock required emergent fluid resuscitation to restore tissue perfusion, minimize end-organ injury, and prevent cardiovascular collapse. In several cases, the rapid reversal of hypotension may have prevented additional procedures, including the need for vasopressors or emergent endotracheal intubation. This in turn may have further decreased subsequent complications, as emergency intubation may exacerbate hypotension and hypoxemia, which are the most common risk factors for postintubation cardiac arrest. 11, 26 The patients in this case series received a wide range of fluid volumes, from 10 mL/kg up to 200 mL/kg, and clinical response to the fluid bolus was immediately detected by improvements in vital signs, mental status, and/or skin perfusion. One patient had previously received a large volume of fluid via infusion pump and yet needed additional rapid fluid resuscitation for recurrent hypotension. All patients had good outcomes, and none developed clinically evident pulmonary edema or volume overload. The Pediatric Advanced Life Support (PALS) Provider Manual specifically calls for a 20 mL/kg fluid bolus to be given over 5 mins for severe shock with hypovolemia or hypotension, noting that "early recognition and rapid intervention are critical to halting the progression from compensated shock to hypotensive shock to cardiopulmonary failure and cardiac arrest." 17 Similarly, the American
College of Critical Care Medicine (ACCM) guidelines specify that 20 mL/kg of crystalloid fluid be administered within 5 mins of the recognition of septic shock and establishment of vascular access. 18 Both resources advise that repeated 20 mL/kg fluid boluses be administered until tissue perfusion is restored, with careful reassessment after each bolus to ensure there are no signs of volume overload. When cardiogenic shock is suspected, smaller bolus volumes are recommended, with careful monitoring for rales and hepatomegaly or objective evidence of volume overload by bedside ultrasound. 18 A number of barriers lead to inadequate resuscitation in pediatric shock. In fact, the PALS Provider Manual cautions clinicians that inadequate and delayed administration of fluids is common and should be carefully avoided. 17 This is supported by studies showing that fluid administration guidelines are often not achieved. 9, 27 In one large academic center, perfect adherence to ACCM guidelines was achieved in 11% of children presenting with septic shock, and a modified goal of 60 mL/kg over 1 hr was achieved in only 37% of patients. 9 Similarly, two simulation studies conducted with over 50 multidisciplinary teams across 30 EDs showed that teams were able to achieve 60 mL/kg of fluid resuscitation in 15 mins in approximately only half of the cases. 28, 29 Perhaps the most common early barriers to effective fluid resuscitation are the recognition of shock and establishment of vascular access. 30 Once shock is recognized, lack of knowledge of fluid resuscitation guidelines and technical limitations of fluid delivery often delay adequate resuscitation. 28, 31 Current methods of fluid resuscitation, including gravity infusion, IV infusion pumps, pressure bags, and manual syringe techniques, all have drawbacks that limit the ability of providers to achieve fluid delivery goals. 15, 16, 32, 33 Another factor limiting effective early resuscitation may be the recent literature suggesting harm from fluid bolus therapy, 34, 35 leading to arguments against the use of early fluid bolus therapy in both adult and pediatric septic shock. 36, 37 The applicability of these studies to emergency pediatric care in the developed world has been questioned and their results should be interpreted with caution, though they have been used to argue against the use of early fluid bolus therapy in both adult and pediatric septic shock guidelines. 36, 37 The most well known of these is the FEAST trial, which randomized children in sub-Saharan Africa with severe febrile illness to fluid bolus therapy vs no fluid bolus. Children who received fluid boluses had increased mortality at 48 hrs. However, it is important to note that children with hypotension were not randomized to the no-bolus arm. 34 In addition, approximately 60% of children were positive for malaria, 30% had severe anemia with hemoglobin <5 mg/dL, and supportive therapies such as high-flow nasal cannula oxygen, mechanical ventilation, and intensive care facilities were not available. For all of these reasons, the results of these studies should be interpreted with caution and are likely not applicable to the resuscitation of decompensated shock in the developed world. A more recent trial by Sankar et al showed an increased rate of mechanical ventilation among children who received their initial fluid bolus over 15 mins. However, this study had a number of methodologic limitations. Investigators enrolled children with low to moderate severity of illness, had a low threshold to determine the need for mechanical ventilation, did not use objective measures of intravascular volume. 35, 38 This study actually showed a trend toward decreased mortality in children who received fluids more rapidly. 35 
Conclusion
While the appropriate timing and volume of fluids for children with sepsis remain a matter of debate, and several ongoing trials are attempting to study this question, 39, 40 it is widely accepted that children with decompensated shock and hypotension require rapid restoration of intravascular volume. The available evidence suggests that earlier reversal of shock improves patient outcomes, and pediatric septic shock guidelines continue to recommend early recognition and treatment with IV fluids. Given the current barriers to early and rapid fluid administration in critically ill patients, a new technique that offers improved speed, efficiency, and control of volume infused has the potential to improve outcomes. This case series demonstrates that the LifeFlow device can be safely and effectively used to reverse shock due to a variety of conditions, potentially reducing the need for further interventions, such as additional fluid bolus therapy, vasopressors, central venous catheters, and endotracheal intubation. The LifeFlow device improves upon standard techniques for the delivery of targeted rapid fluid resuscitation therapy. This device improves the speed and efficiency of care for children with sepsis and other forms of shock, potentially reducing the mortality, morbidity, and cost associated with these conditions. Prospective trials are currently underway to further evaluate the effects of this fluid resuscitation technique.
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